We’re excited to share that ModelOp CEO Pete Foley has been featured in Pharm Exec with a new article titled “$25B Potential in Accelerating AI’s Impact and Value in Pharma.” In it, Pete explores how pharmaceutical companies can navigate the complexities of enterprise AI, reduce time-to-market, and track measurable ROI across the AI lifecycle.
With AI investment in pharma projected to grow from $4B to $25B by 2030, the opportunity—and the urgency—for effective governance has never been greater. Pete highlights the governance and scaling challenges pharma companies face, and details how ModelOp’s Minimum Viable Governance (MVG) framework can be applied specifically to the pharmaceutical industry.
MVG empowers pharma organizations to:
- Build real-time visibility across all AI initiatives
- Enforce lightweight, scalable governance policies
- Drive ROI through AI portfolio intelligence and better resource allocation
Whether you’re deploying GenAI in early-stage drug discovery or automating clinical trial recruitment, the path to value starts with visibility, accountability, and a clear governance framework.
